You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Histone Deacetylase Inhibitors Protect against and Mitigate the Lethality of Total-Body Irradiation in Mice
Stephen L. Brown, Andrew Kolozsvary, Jianguo Liu, Samuel Ryu and Jae Ho Kim
Vol. 169, No. 4 (Apr., 2008), pp. 474-478
Published by: Radiation Research Society
Stable URL: http://www.jstor.org/stable/30132984
Page Count: 5
You can always find the topics here!Topics: Histone deacetylase inhibitors, Radiation dosage, Histones, Stem cells, Spleen, Bone marrow, Irradiation, Hematopoietic stem cells, Radiation injuries, Bone marrow cells
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
It was hypothesized that histone deacetylase (HDAC) inhibitors may increase survival after total-body irradiation (TBI) based on previous reports demonstrating that HDAC inhibitors stimulate the proliferation of bone marrow stem cells. Using the time for mice to lose 20% or more of their weight as the end point, two HDAC inhibitors, valproic acid and trichostatin-A, were found to reduce lethality in a dose-dependent manner. HDAC inhibitors were effective at reducing lethality when given either 24 h before or 1 h after TBI. The results indicate that HDAC inhibitors have potential for protecting against and mitigating radiation-induced lethality.
Radiation Research © 2008 Radiation Research Society